Match!
Celina Ang
Icahn School of Medicine at Mount Sinai
PathologyOncologyHepatocellular carcinomaColorectal cancerMedicine
40Publications
5H-index
140Citations
What is this?
Publications 35
Newest
#1Imane El Dika (Cornell College)H-Index: 6
#2Robert J. Mayer (Harvard University)H-Index: 102
Last. Celina Ang (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
view all 13 authors...
LESSONS LEARNED: FLC is a complex cancer with many implicated oncogenic pathways. Single or dual targeting does not appear to alter the natural history of the cancer, and novel therapeutics are needed. Estrogen deprivation therapy with letrozole and leuprolide, alone or in combination with the mTOR inhibitor, everolimus, did not demonstrate clinical activity in advanced fibrolamellar carcinoma. The study drugs were well tolerated when administered as single agents or in combination in this patie...
1 CitationsSource
#1David J. Pinato (Imperial College London)H-Index: 20
#2Ahmed Omar Kaseb (University of Texas MD Anderson Cancer Center)H-Index: 30
Last. Neil Satish Nimkar (New York Methodist Hospital)
view all 20 authors...
531Background: The impact of corticosteroid treatment (CT) on the efficacy of immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC) is undefined. We evaluated whether CT administered...
Source
Last. Celina AngH-Index: 5
view all 3 authors...
Source
OBJECTIVE:In the United States, hepatocellular carcinoma (HCC) is more common among communities with low socioeconomic status (SES), and these groups tend to be diagnosed with later-stage cancers. Sorafenib is the primary treatment for advanced HCC, however its substantial cost raises concern for access to treatment. METHODS:The newly developed Case-Background method was used to estimate odds ratios for the impacts of various sociodemographic factors on sorafenib access in clinically eligible pa...
1 CitationsSource
#1Celina Ang (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Anthony F. Shields (WSU: Wayne State University)H-Index: 43
Last. John L. Marshall (Georgetown University)H-Index: 46
view all 10 authors...
// Celina Ang 1 , Anthony Shields 2 , Joanne Xiu 3 , Zoran Gatalica 4 , Sandeep Reddy 3 , Mohamed E. Salem 5 , Carol Farhangfar 6 , Jimmy Hwang 7 , Igor Astsaturov 3, 7 and John L. Marshall 5 1 Department of Medicine, Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA 2 Department of Oncology, Molecular Imaging & Diagnostics Program, Karmanos Cancer Center, Wayne State University, Detroit, MI, USA 3 Department of Medical Affairs, Caris Life Sciences, Phoenix, AZ, USA...
1 CitationsSource
#1Celina AngH-Index: 5
#2Aryeh StollmanH-Index: 1
Last. Sherri Z. MillisH-Index: 1
view all 7 authors...
We report the case of a patient with appendiceal adenocarcinoma with mucinous peritoneal carcinomatosis who was treated with trametinib upon identification of a GNAS R201H mutation
2 CitationsSource
#1Celina AngH-Index: 5
#2Aatur D. SinghiH-Index: 23
Last. Sherri Z. MillisH-Index: 13
view all 8 authors...
599Background: Appendiceal cancers are rare and consist of mucinous (M), adenocarcinoma (A), goblet cell carcinoma (GCC), pseudomyxoma peritonei (PMP), and several even rarer histologies. Current treatment involves surgical resection or debulking; no standard exists for adjuvant chemotherapy or metastatic disease treatment. Systemic treatment is often based on chemotherapy regimens used in colorectal cancer. Methods: Tissue from 518 appendiceal cancer patients was assayed by hybrid-capture based...
Source
#1Celina AngH-Index: 5
#2Anthony F. ShieldsH-Index: 43
Last. John MarshallH-Index: 77
view all 10 authors...
Source
#1Celina AngH-Index: 5
#2Umut Ozbek (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 9
Last. Randall F. Holcombe (Mount Sinai Hospital)H-Index: 3
view all 8 authors...
e15162Background: IBD (Crohn's disease (CD) and ulcerative colitis (UC)) is a risk factor for CRC. Chemotherapy toxicity may exacerbate IBD symptoms and vice versa but data are limited. Methods: Me...
Source
#1John Michael Rozehnal (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Celina Ang (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 5
Last. Krzysztof Misiukiewicz (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 12
view all 10 authors...
e23127Background: The availability of commercial tumor molecular profiling services enables clinicians to identify and drug “actionable” targets, with the aim of personalizing therapy. However, it ...
Source
1234